trial

Nicotinic Receptors and Schizophrenia

NCTId NCT02538081
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by VA Office of Research and Development
Primary completion 2016-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2015-08
Primary completion
2016-08
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
Risperidone

Sponsors

VA Office of Research and DevelopmentLead Sponsor
University of Colorado, DenverCollaborator

Investigators

1
Robert Freedman, MDPrincipal Investigator

Sites

1 total
Denver, United States

Linked catalysts

1
Nicotinic Receptors and Schizophrenia — primary completion2016-08

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE1,PHASE2
Primary Completion Date
2016-08
Status
WITHDRAWN
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
VA Office of Research and Development
company
collaborator
University of Colorado, Denver
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Robert Freedman, MD
person